Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $145.29, for a total transaction of $435,870.00. Following the completion of the sale, the chief financial officer owned 164,096 shares of the company’s stock, valued at $23,841,507.84. This trade represents a 1.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Trading Up 0.9%

NASDAQ GILD traded up $1.38 on Wednesday, reaching $147.68. The stock had a trading volume of 5,078,675 shares, compared to its average volume of 6,907,595. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a fifty day moving average price of $139.02 and a two-hundred day moving average price of $136.18. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The firm has a market capitalization of $183.12 billion, a price-to-earnings ratio of -55.31 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same period last year, the business posted $2.01 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead expanded six royalty-free voluntary licensing agreements to include the investigational once-yearly formulation of lenacapavir for HIV pre-exposure prophylaxis. The agreements cover 120 primarily low- and lower-middle-income countries and support manufacturing readiness, technology transfer and future supply planning. The move strengthens Gilead’s global HIV-prevention strategy and could broaden the treatment’s long-term reach if approved. Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
• Positive Sentiment: Gilead and the Pan American Health Organization agreed to expand access to twice-yearly lenacapavir across Latin America and the Caribbean, adding 14 countries to the company’s access efforts. Broader distribution may support future commercial adoption and reinforces lenacapavir’s growth potential in HIV prevention. Gilead and PAHO Announce Lenacapavir Partnership
• Neutral Sentiment: The licensing and PAHO announcements are strategically favorable but are not expected to produce an immediate material revenue contribution, since access agreements emphasize affordability and the once-yearly product remains subject to clinical and regulatory approval.
• Negative Sentiment: Gilead’s $0.82-per-share dividend went ex-dividend on September 15. The resulting mechanical share-price adjustment can create short-term pressure, though the payout remains supportive for income-focused investors. Gilead Sciences Dividend Analysis

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on GILD shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Zacks Research raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 31st. Barclays dropped their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. HSBC increased their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $158.78.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. BlackRock Inc. purchased a new position in Gilead Sciences in the second quarter valued at approximately $15,393,785,000. Norges Bank purchased a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $2,617,152,000. Legal & General Group Plc purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $1,316,606,000. Deutsche Bank AG acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $918,387,000. Finally, Boston Partners acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $517,808,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.